CU24512B1 - Derivados de oxopiridina sustituidos - Google Patents

Derivados de oxopiridina sustituidos

Info

Publication number
CU24512B1
CU24512B1 CU2018000001A CU20180001A CU24512B1 CU 24512 B1 CU24512 B1 CU 24512B1 CU 2018000001 A CU2018000001 A CU 2018000001A CU 20180001 A CU20180001 A CU 20180001A CU 24512 B1 CU24512 B1 CU 24512B1
Authority
CU
Cuba
Prior art keywords
formula
substitute
oxopyridine derivatives
derivatives
humans
Prior art date
Application number
CU2018000001A
Other languages
English (en)
Other versions
CU20180001A7 (es
Inventor
Dr Jens Ackerstaff
Dr Pascal Ellerbrock
Stefan Heitmeier
Prof Dr Alexander Hillisch
Nuñez Dr Eloisa Jimenez
Dr Dieter Lang
Dr Daniel Meibom
Dr Katharina Meier
Dr Susanne Röhrig
Dr Jan Stampfuss
Dr Adrian Tersteegen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20180001A7 publication Critical patent/CU20180001A7/es
Publication of CU24512B1 publication Critical patent/CU24512B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

<p>La invención se refiere a derivados de oxopiridina sustituidos de fórmula (I)</p> <p>ESPACIO PARA FÓRMULA (I)</p> <p>los cuales se presentan como inhibidores del factor XIa altamente potentes con un comportamiento farmacocinético significativamente potenciado, en particular una mayor exposición de dicho compuesto en la sangre por encima de la concentración eficaz mínima dentro de un intervalo de dosificación dado. Estos compuestos son útiles para el tratamiento de trastornos cardiovasculares, en particular de trastornos trombóticos o tromboembólicos, en humanos y animales.</p>
CU2018000001A 2015-07-09 2016-07-05 Derivados de oxopiridina sustituidos CU24512B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176099 2015-07-09
EP16157350 2016-02-25
PCT/EP2016/065787 WO2017005725A1 (en) 2015-07-09 2016-07-05 Substituted oxopyridine derivatives

Publications (2)

Publication Number Publication Date
CU20180001A7 CU20180001A7 (es) 2018-06-05
CU24512B1 true CU24512B1 (es) 2021-05-12

Family

ID=56345141

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000001A CU24512B1 (es) 2015-07-09 2016-07-05 Derivados de oxopiridina sustituidos

Country Status (39)

Country Link
US (4) US10421742B2 (es)
EP (1) EP3319956B1 (es)
JP (1) JP6871180B2 (es)
KR (1) KR102596164B1 (es)
CN (2) CN113292539B (es)
AU (1) AU2016289746B2 (es)
CA (1) CA2990901C (es)
CL (1) CL2018000039A1 (es)
CO (1) CO2018000113A2 (es)
CR (1) CR20180017A (es)
CU (1) CU24512B1 (es)
CY (1) CY1123996T1 (es)
DK (1) DK3319956T3 (es)
DO (1) DOP2018000004A (es)
EA (1) EA036208B1 (es)
EC (1) ECSP18001308A (es)
ES (1) ES2856554T3 (es)
GE (1) GEP20197046B (es)
HR (1) HRP20210459T1 (es)
HU (1) HUE053552T2 (es)
IL (1) IL256556B (es)
JO (1) JO3703B1 (es)
LT (1) LT3319956T (es)
MA (1) MA42376B1 (es)
MX (1) MX377903B (es)
MY (1) MY196640A (es)
NI (1) NI201800001A (es)
PE (1) PE20180538A1 (es)
PH (1) PH12018500057A1 (es)
PL (1) PL3319956T3 (es)
RS (1) RS61584B1 (es)
SI (1) SI3319956T1 (es)
SV (1) SV2018005610A (es)
TN (1) TN2018000011A1 (es)
TW (1) TWI717367B (es)
UA (1) UA122341C2 (es)
UY (1) UY36780A (es)
WO (1) WO2017005725A1 (es)
ZA (1) ZA201800826B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046158A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
HK1247615A1 (zh) * 2015-03-19 2018-09-28 Bayer Pharma Aktiengesellschaft 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
PT3486242T (pt) 2016-08-31 2022-01-06 Jiangsu Hengrui Medicine Co Derivado de oxopicolinamida, método de preparação para esse fim e utilização farmacêutica do mesmo
IL300463A (en) * 2018-03-15 2023-04-01 Bayer Pharma AG Process for the preparation of two derivatives of 4-{[(2S)-2-{4-[5-chloro-2-(1H-3,2,1-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridine -1-(2H)-yl}butenoyl]amino}-2-fluorobenzamide
PE20210165A1 (es) 2018-04-10 2021-01-26 Bayer Pharma AG Un derivado de oxopiridina sustituido
WO2020007256A1 (zh) 2018-07-02 2020-01-09 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的晶型及制备方法
AR115870A1 (es) 2018-07-31 2021-03-10 Sumitomo Chemical Co MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
WO2020126682A1 (en) 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
MX2021007508A (es) 2018-12-21 2021-08-05 Bayer Ag Derivados de oxopiridina sustituidos.
US20220144848A1 (en) 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
MX2022003649A (es) * 2019-09-27 2022-06-08 Shenzhen Salubris Pharm Co Ltd Inhibidores del fxia y metodo de preparacion de los mismos y uso farmaceutico de los mismos.
JP7700218B2 (ja) 2020-09-17 2025-06-30 浙江海正薬業股▲ふん▼有限公司 ピペラジン誘導体、その製造方法、およびその使用
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
CA3212644A1 (en) * 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
BR112023016298A2 (pt) 2021-03-09 2023-10-03 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
CN113666826B (zh) * 2021-07-30 2024-03-26 五邑大学 一种芳基或杂芳基甲氧基化反应的方法
CN116199672A (zh) * 2021-11-30 2023-06-02 成都泰和伟业生物科技有限公司 一种嘧啶酰胺类衍生物及其制备方法和用途
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
CN116262736B (zh) * 2022-12-26 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
KR20250164210A (ko) 2023-03-31 2025-11-24 바이엘 악티엔게젤샤프트 (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-디벤제나헵타판-74-카르복스아미드를포함하는 제약 투여 형태
WO2024251276A1 (zh) 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体和应用
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN118894814B (zh) * 2024-07-15 2025-09-12 上海康鹏科技股份有限公司 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1，2，3-三唑的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1526131A1 (en) 2003-10-22 2005-04-27 Graffinity Pharmaceuticals Aktiengesellschaft Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2766347B1 (en) 2011-10-14 2016-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
EP2794597B1 (en) * 2011-12-21 2017-11-15 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
EA028581B1 (ru) * 2012-08-03 2017-12-29 Бристол-Маерс Сквибб Компани ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa
EP2968207A4 (en) 2013-03-14 2016-09-28 Chdi Foundation Inc HISTON DEACETYLASE INHIBITORS AND COMPOSITIONS
EP2978425B1 (en) * 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
CN105555767B (zh) 2013-07-23 2018-03-23 拜耳制药股份公司 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
ES2659045T3 (es) * 2013-10-30 2018-03-13 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
UY40230A (es) 2014-01-31 2023-08-15 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden
CN105829298B (zh) * 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2016046159A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US20170298052A1 (en) 2014-09-24 2017-10-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046158A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US10167280B2 (en) 2014-09-24 2019-01-01 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046156A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046157A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017023992A1 (en) * 2015-08-05 2017-02-09 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors

Also Published As

Publication number Publication date
CN113292539A (zh) 2021-08-24
US20250282748A1 (en) 2025-09-11
JP6871180B2 (ja) 2021-05-12
CA2990901A1 (en) 2017-01-12
HUE053552T2 (hu) 2021-07-28
NZ739109A (en) 2024-09-27
MA42376A (fr) 2018-05-16
PE20180538A1 (es) 2018-03-20
HK1255045A1 (zh) 2019-08-02
CA2990901C (en) 2024-11-12
US20180194745A1 (en) 2018-07-12
TN2018000011A1 (en) 2019-07-08
ECSP18001308A (es) 2018-03-31
HRP20210459T1 (hr) 2021-05-14
EA201890111A1 (ru) 2018-06-29
BR112018000209A2 (pt) 2018-09-04
ZA201800826B (en) 2021-08-25
UY36780A (es) 2017-01-31
IL256556A (en) 2018-02-28
EP3319956B1 (en) 2021-01-06
NI201800001A (es) 2018-10-19
AU2016289746A1 (en) 2018-01-25
US11180471B2 (en) 2021-11-23
SV2018005610A (es) 2018-04-27
MX377903B (es) 2025-03-10
CN113292539B (zh) 2023-12-22
PH12018500057A1 (en) 2018-07-09
TW201706261A (zh) 2017-02-16
CN108026072B (zh) 2021-08-17
JO3703B1 (ar) 2021-01-31
MX2018000076A (es) 2018-02-26
GEP20197046B (en) 2019-12-10
KR102596164B1 (ko) 2023-11-01
MY196640A (en) 2023-04-25
CU20180001A7 (es) 2018-06-05
MA42376B1 (fr) 2021-04-30
UA122341C2 (uk) 2020-10-26
DK3319956T3 (da) 2021-03-29
JP2018519323A (ja) 2018-07-19
EP3319956A1 (en) 2018-05-16
CY1123996T1 (el) 2022-07-22
LT3319956T (lt) 2021-02-10
US20190367478A1 (en) 2019-12-05
AU2016289746B2 (en) 2020-08-20
US10421742B2 (en) 2019-09-24
PL3319956T3 (pl) 2021-07-05
SI3319956T1 (sl) 2021-02-26
CN108026072A (zh) 2018-05-11
WO2017005725A1 (en) 2017-01-12
ES2856554T3 (es) 2021-09-27
CR20180017A (es) 2018-03-07
US20230024752A1 (en) 2023-01-26
DOP2018000004A (es) 2018-01-31
CL2018000039A1 (es) 2018-07-13
TWI717367B (zh) 2021-02-01
IL256556B (en) 2021-02-28
RS61584B1 (sr) 2021-04-29
KR20180026761A (ko) 2018-03-13
EA036208B1 (ru) 2020-10-14
CO2018000113A2 (es) 2018-06-12

Similar Documents

Publication Publication Date Title
CU24512B1 (es) Derivados de oxopiridina sustituidos
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2018006148A (es) Inhibidores de cxcr2.
MX378343B (es) Derivados de 3-fenil-benzofuran-2-ona que contienen fosforo como estabilizantes.
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2017002994A1 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
UY35972A (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
CR20150517A (es) Inhibidores de la phd de 6-(5-hidroxi-1h-pirazol-1-il) nicotinamida
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
CY1122813T1 (el) Διαλυτος cd33 για την αγωγη μυελοδυσπλαστικων συνδρομων (μds)
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
MX2019006893A (es) Inhibidores heterociclicos de mct4.
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
MX2017001645A (es) Derivados de difosfito de 3-fenil-benzofuran-2-ona- como estabilizantes.
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias